Views: 0 Author: Site Editor Publish Time: 2025-09-24 Origin: Site
The story of Diosmin Hesperidin 90:10 is a remarkable example of how a natural flavonoid compound evolved from botanical discovery to large-scale pharmaceutical use. Today, with advances like Micronized Diosmin Hesperidin absorption improvement, this combination has become a cornerstone in venotonic therapy worldwide, supported by leading api suppliers and pharmaceutical raw material suppliers.
Diosmin is a flavonoid glycoside first isolated from citrus fruit peels, particularly oranges and grapefruits. In 1925, French scientists H. Horhammer and E. Wagner were the first to identify and describe the compound’s chemical structure. The name “Diosmin” derives from the plant genus Diospyros combined with flavonoid nomenclature.
At that time, diosmin was purely a natural curiosity—recognized for its antioxidant and anti-inflammatory potential, but limited in availability due to its extremely low concentration in natural citrus sources.
By the 1960s, researchers discovered a transformative approach: converting hesperidin, a citrus bioflavonoid abundantly found in orange peels, into diosmin through selective hydrolysis and oxidation. This innovation solved the bottleneck of raw material scarcity and enabled diosmin to be produced on an industrial scale.
This breakthrough not only reduced costs but also made diosmin widely accessible for pharmaceutical development. From this point forward, active pharmaceutical ingredient manufacturers in China and Europe began refining processes for consistent quality and higher yields.
The first major leap into clinical application occurred in the 1960s when French pharmaceutical company Servier began developing diosmin as a vascular-protective drug. By the 1970s, the introduction of Daflon®, a formulation containing Diosmin Hesperidin 90:10, became a major milestone.
This fixed ratio was chosen for its synergistic action:
Diosmin Hesperidin venotonic effect: Diosmin enhances venous tone and reduces vein dilation, while hesperidin improves capillary resistance and lowers permeability. Together, they improve venous return and relieve symptoms like heaviness, swelling, and cramps.
Anti-inflammatory and antioxidant synergy: Both flavonoids inhibit inflammatory mediators (TNF-α, IL-6, LTB4) and oxidative stress, protecting vascular tissues.
Lymphatic drainage support: Clinical data confirmed that the 90:10 ratio promotes lymphatic return and reduces tissue fluid retention, offering superior relief from edema compared with monotherapy.
Over time, this formulation became the international standard, included in European treatment guidelines for chronic venous insufficiency and hemorrhoidal disease.
While the therapeutic potential of diosmin and hesperidin was clear, a challenge remained: their poor water solubility limited oral bioavailability. This led to the development of Micronized Diosmin Hesperidin, where the particle size is reduced dramatically to improve gastrointestinal absorption.
Micronized Diosmin Hesperidin absorption improvement has been demonstrated in clinical studies, showing higher plasma concentrations, faster onset, and greater symptom relief compared with non-micronized forms.
The result is a more reliable and consistent therapeutic response, especially critical in long-term management of venous diseases.
This micronization technology transformed Diosmin Hesperidin MPFF (Micronized Purified Flavonoid Fraction) into one of the most trusted and widely prescribed venotonic therapies worldwide.
The well-documented Diosmin Hesperidin MPFF mechanisms: improves venous tone & lymphatic drainage are central to its clinical success. Research highlights the following key effects:
Improved venous tone: By prolonging norepinephrine activity on venous walls, diosmin increases venous contractility, reducing stasis and reflux.
Enhanced lymphatic drainage: Both compounds stimulate lymphatic contractions, leading to better removal of interstitial fluid.
Microcirculation protection: The combination reduces leukocyte adhesion and capillary leakage, preventing skin and tissue complications such as venous ulcers.
These mechanisms explain why the 90:10 formulation continues to be the gold standard in phlebotropic therapy.
The growing demand for diosmin and hesperidin APIs has positioned China as one of the leading hubs for active pharmaceutical ingredient manufacturers. With advanced process development, high-quality production standards, and regulatory compliance, Chinese pharmaceutical raw material suppliers are now key players in the global supply chain.
For companies seeking Diosmin Hesperidin 90:10 supplier 99% purity bulk, the emphasis is on consistency, scalability, and regulatory readiness. Micronization technology has further raised the bar, ensuring that diosmin hesperidin products meet international standards for efficacy and safety.
From its first isolation in 1925 to its industrial-scale production and eventual clinical dominance as a Micronized Diosmin Hesperidin formulation, the journey of diosmin is a testament to the evolution of natural product–based medicine. Today, the Diosmin Hesperidin 90:10 ratio remains the clinically proven choice for venotonic therapy, thanks to its synergistic action on venous tone, lymphatic drainage, and microcirculation.
Supported by innovation in absorption technology and by reliable api suppliers worldwide, this compound continues to define standards in chronic venous disease management. For global pharmaceutical raw material suppliers, diosmin’s path from discovery to advanced formulations illustrates how science, technology, and supply chain excellence converge to meet critical healthcare needs.
